Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Bhami'S Research Laboratory Pvt Ltd. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, reflecting a focused approach to its current patent applications. With 1 pending action currently active, the company's immediate prosecution workload is limited to a single ongoing dialogue with the patent office. This level of activity indicates that the applicant is currently navigating a narrow technical path in its intellectual property development.
The administrative oversight for this portfolio is concentrated in 1 distinct art unit, which ensures that the technical review is handled by a single specialized group. KIM, YUNSOO is identified as the busiest examiner, currently overseeing 1 pending office action. Since this examiner manages the assigned matter, the company's entire active patent strategy is currently focused on the findings of this one individual. This concentration requires a precise response to the specific rejections or objections raised by this examiner in the single pending case to achieve a favorable outcome.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18345163 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18345163 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18345163 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | KIM, YUNSOO | 1641 | §103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBhami'S Research Laboratory Pvt Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yunsoo Kim has the most, with 1 of Bhami'S Research Laboratory Pvt Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
